Marazzi G, et al. – Researchers evaluated whether a higher proportion of high-risk patients can achieve target low-density lipoprotein cholesterol (LDL-C) with low-dose statin (LDS) in combination with ezetimibe (EZE) or LDS plus nutraceutical (Armolipid Plus [ALP] containing red yeast rice, policosanol, and berberine) in this randomized, prospective, parallel-group, single-blind study. Participants included 100 patients with coronary artery disease (CAD) who had undergone percutaneous coronary intervention in the preceding 12 months, were intolerant to high-dose statin (HDS), and were not at LDL-C target (< 70 mg/dL) with LDS alone. They also assessed the efficacy of triple combination LDS+EZE+ALP in resistant patients (LDL-C > 70 mg/dL). Findings revealed that most HDS-intolerant CAD patients reached target LDL-C within 3-6 months of receiving LDS plus EZE and/or ALP and, therefore, treatment with LDS plus EZE and/or ALP represents a valuable therapeutic option for such patients.